SEC Form 4															
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity	STAT		l pursu	uant to	o Secti	on 16	(a) of the Secu e Investment (urities Excha	inge Act of		RSHIP	Estim		er: verage burde sponse:	3235-0287 en 0.5
securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
1. Name and Address of Reporting Pers <u>Alpern Robert J</u>		2. Issuer Name and Ticker or Trading Symbol <u>AbbVie Inc.</u> [ABBV]								5. Relationship of Reporting Person(s) to Iss (Check all applicable)					
(Last) (First) 1 N. WAUKEGAN ROAD				3. Date of Earliest Transaction (Month/Day/Year) 09/30/2024							Officer (give title Other (specify below) below)				specify
(Street) NORTH IL 60064 CHICAGO			Line)								ine) 🔽 Form	l or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting erson			
(City) (State)	(Zip)														
			-Derivative S 2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date		4. Secur	of, or Benefi ities Acquired (A) d Of (D) (Instr. 3, 4		nd Securitie Benefici Owned I	int of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code V	Amount	(A) o (D)	r Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3) 2. 3. Transaction Date (Month/Day/Yes Derivative Security	3A. Deemed Execution D if any (Month/Day/	ate, Ti C	4. Transactic Code (Inst 8)		5. Number on of		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title an Amount o Securities Underlyin Derivative (Instr. 3 ar	f g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s lly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
		c	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Numbe of Shares					
Stock Equivalent Units \$197.48 09/30/2024			Α		37		(1)	(1)	Common Stock	37	\$197.48	9,655 ⁽²	2)	D	

Explanation of Responses:

1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in respectively a consistence of the stock equivalent units in the Above Laboratories and Above. The stock equivalent units in the Above account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

T.O. Odutayo, Attorney-in-Fact 10/02/2024

for Robert J. Alpern

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.